Topic summary

Coming back to: When "no data" is the complete and final answer

Compounds › Other compounds research use only needs a source custom synthesis

This is a generated summary. It shows the 9 most-liked posts from a topic of 83, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

h.almeidaTL2Member31 May 2025 · edited#3

Everything in the opening post holds. The case it does not cover is the one I have.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

26 likes 14mo

k.bettencourtTL2Member20 Jun 2025#19

h.almeida, post #3: Everything in the opening post holds. The case it does not cover is the one I have. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. Go to post

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

Take it as a starting point and not as a specification.

27 likes in reply to #3 13mo

y.mensahTL3Wiki editor24 Jun 2025#23

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

29 likes 13mo

s.cardosoTL24 Jul 2025#33

The arithmetic in post #32 is right; the assumption feeding it is the part to check.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I would rather say I do not know than round it up to an answer.

31 likes 13mo

v.klausenTL3Regular10 Jul 2025#40

b.petrov, post #34: Answering the question post #30 raises rather than the one it answers. Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages. Go to post

I had written a reply contradicting post #38 and deleted it. Here is what survived.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

29 likes in reply to #34 13mo

n.petrovTL224 Jul 2025#57

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

It is the sort of thing that seems obvious in retrospect and was not at the time.

28 likes 12mo

s.vukovicTL231 Jul 2025#66

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

27 likes 12mo

a.cabreraTL29 Aug 2025 · edited#78

r.mensa, post #47: Grateful for the specificity. Vague answers to this question are what sent me looking. Go to post

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

A modest claim, modestly supported.

29 likes in reply to #47 12mo

endpoint_traceTL1Member12 Aug 2025#82

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

Marking that as an opinion rather than a finding.

33 likes 11mo

Read the full topic (83 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…	+154	165	6.3k	15mo
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…	+109	125	2k	16mo
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+35	39	688	5mo
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…	+107	119	11k	12mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…	+81	87	35k	10mo

Related topics — sharing the tags research use only, needs a source, custom synthesis

Topic	Participants	Replies	Views	Activity
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…	+135	163	46k	17mo
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 needs a source Closed GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. GHRH analogues versus ghrelin mimetics — I…	+9	13	249	17mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…	+64	71	2.5k	13mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…	+23	27	7.7k	15mo
Second pass at: Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data ipamorelin tesamorelin needs a source Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. A comparison question rather than a question about one compound.…	+120	129	61k	11mo